Abstract: This method relates to a method for the production of fully disproportionated rosin by treating rosin with sulfur and an alkylphenol sulfide compound of a particular structure.

Abstract: The present invention relates to a method for treating an inkjet recording element to improve the image quality of such an element. The method comprises the applying of a solution of an aluminosilicate polymer on said recording element, said aluminosilicate polymer being obtainable by a preparation method consisting in treating an aluminum halide with an alkyl orthosilicate only having hydrolisable substituents or with a mixture of at least one silicon alcoxide only having hydrolisable substituents and at least one silicon alcoxide having a non-hydrolisable substituent with an aqueous alkali in the presence of silanol groups, the aluminum concentration being maintained less than 0.3 mol/l, the Al/Si molar ratio being maintained between 1 and 3.6 and the alkali/Al molar ratio being maintained between 2.

Abstract: A method for preparing polyorganosiloxanes (POS) by a ring-opening polymerization and/or linear, non-linear or cyclic POS redistribution in the presence of a nucleophilic carbene. The initial efficiency of the POS conversion is substantially increased at low temperature, resulting in less residual content of initial POS.

Abstract: The present invention includes a composition for a silicon-containing material used as an etch mask for underlying layers. More specifically, the silicon-containing material may be used as an etch mask for a patterned imprinted layer comprising protrusions and recessions. To that end, in one embodiment of the present invention, the composition includes a hydroxyl-functional silicone component, a cross-linking component, a catalyst component, and a solvent. This composition allows the silicon-containing material to selectively etch the protrusions and the segments of the patterned imprinting layer in superimposition therewith, while minimizing the etching of the segments in superposition with the recessions, and therefore allowing an in-situ hardened mask to be created by the silicon-containing material, with the hardened mask and the patterned imprinting layer forming a substantially planarized profile.

Abstract: A photocurable and thermosetting coating composition which is solventless and liquid at room temperature is provided. This coating composition provides scratch resistance, crack resistance, smudge resistance, and removability of oil-base felted markers by wiping with the underlying substrate, and this coating composition contains a silicone resin represented by: (R1R2R3SiO1/2)a(R4R5SiO2/2)b(R6SiO3/2)c(SiO4/2)d(O1/2X)e ??(1) wherein X is hydrogen atom or an alkyl group; R1 to R6 are respectively at least one monovalent organic group which is a monovalent aliphatic hydrocarbon group or a monovalent aromatic hydrocarbon group optionally substituted with a substituent such as a poly(hexafluoropropylene oxide) structure-containing group; a, b, d, and e are 0 or a positive number; c is a positive number; and a+b+c+d is 1. The silicone resin contains at least one group represented by: CH2?C(R7)COOCH2— ??(2) wherein R7 is hydrogen atom or methyl group.

Abstract: The present invention relates to cast polyurethane elastomers of high resilience, clarity, and attractive abrasion resistance derived from polyurethane systems comprising a customized selection of polycaprolactone polyol incorporated into the isocyanate and/or isocyanate-reactive composition.

Abstract: The present invention relates to an isocyanate-terminated prepolymer composition obtained from reaction of a methylene diphenylisocyanate, comprising at least 25 weight percent of the 2,4?- isomer, with a polycaprolactone polyol; and to polyurethane or polyurea elastomers obtained from the said isocyanate-terminated prepolymer composition.

Abstract: A method for producing a capped poly(arylene ether) having a low concentration of metal impurities is described. The method includes treating a solution of a capped poly(arylene ether) with a chelant to bind the polymerization catalyst metal, and separating the chelated metal from the capped poly(arylene ether). Capped poly(arylene ether)s prepared by the method are also described, as are curable compositions that include them.

Abstract: The present invention is drawn to an aqueous composition containing: (a) at least one polyamine compound comprising at least three amino groups; (b) at least one nonionic surfactant; (c) at least one compound chosen from an alkyl ether carboxylic acid, an alkyl ether carboxylate, a fatty acid having from about 6 to about 40 carbon atoms, and mixtures thereof; and (d) at least one water-insoluble material, and wherein the composition is both homogeneous and clear to substantially clear in appearance.

Abstract: The present invention relates to polycarbonate having repeat units derived from tert-butylhydroquinone (TBHQ). It has herein been found that polycarbonate having repeat units derived from TBHQ has superior properties as compared to polycarbonate having repeat units derived from other dihydroxy (hydroquinone-type) compounds. In one embodiment the present invention provides a polycarbonate having repeat units derived from tert-butylhydroquinone. The polycarbonate has a Mw (PC) of at least 9,000 g/mol.

Abstract: The present invention provides an optical semiconductor sealing material comprising a radically polymerized polymer of a methacrylate ester having an alicyclic hydrocarbon group containing 7 or more carbon atoms e.g. an adamantyl group, a norbornyl group or a dicyclopentanyl group; and an optical semiconductor sealing material comprising a radically polymerized polymer of 50 to 97 mass % of the methacrylate ester and 3 to 50 mass % of acrylate ester having a hydroxyl group. The optical semiconductor sealing material of the present invention is highly transparent and stable to UV light and thus does not undergo yellowing. In addition, the material exhibits excellent compatibility between heat resistance and refractive index, does not undergo deformation or cracking during heating processes such as reflow soldering, and shows high processability.

Abstract: Disclosed is a polyimide film which exhibits high adherability to a metal foil via an adhesive layer containing a thermoplastic polyimide without requiring a special surface treatment. Specifically disclosed is a non-thermoplastic polyimide film obtained by imidizing a polyamic acid solution which is obtained from aromatic diamine and aromatic acid dianhydride. This non-thermoplastic polyimide film is characterized in that the aromatic diamine contains 4,4?-diaminodiphenylether and bis{4-(4-aminophenoxy)phenyl}propane, and the solution containing a polyamic acid is obtained by a specific production method.

Abstract: This invention provides a polylactic acid resin composition in which stereocomplex crystals of poly-L-lactic acid and poly-D-lactic acid can be selectively crystallized to obtain polylactic acid having a sufficiently high speed of crystallization and a sufficiently high ratio of stereocomplex crystal and a molded article thereof obtained via melt molding and crystallization of the same. Such polylactic acid resin composition comprises polylactic acid capable of generating stereocomplex crystallization and an aromatic urea compound represented by formula (1): wherein R1 represents an alkylene group having 1 to 10 carbon atoms; R2 represents an alkyl group having 1 to 25 carbon atoms; and m is an integer between 1 to 6.

Abstract: In a process for producing polyarylene sulfide, comprising: reacting an alkali sulfide source and an aromatic dihalide compound in a polar organic solvent to obtain a polymerizate slurry containing polyarylene sulfide particles, by-produced alkali metal salt fine particles and the polar organic solvent, and recovering the polyarylene sulfide particles washed from the polymerizate slurry; the polymerizate slurry is separated by sieving into the polyarylene sulfide particles and a slurry containing the alkali metal salt fine particles, and the separated polyarylene sulfide particles are subjected to a washing step wherein the polyarylene sulfides are introduced into a countercurrent washing apparatus enclosing a movable part and subjected therein to continuous countercurrent contact with a washing liquid. As a result, polyarylene sulfide particles of good quality are produced at a good yield, while pursuing process rationalization.

Abstract: Cross-linkable hole transport polymers comprising at least one first monomer comprised of an arylamine and at least one second monomer comprised of a fluorene, carbazole, diphenylsilicon or fused heterocyclic derivative are provided. In some embodiments, the hole transport polymers also comprise at least one third monomer, different from the second monomer, and comprised of a fluorene, carbazole, diphenylsilicon or fused heterocyclic derivative. Electronic devices made with the polymeric materials are also provided.

Abstract: A process for the preparation of polyoxymethylenes by cationic polymerization of the monomers a) in the presence of initiators b) and, if appropriate, in the presence of regulators c) and subsequent deactivation and isolation of the polymer, wherein the total amount of proton donors is less than 5000 ppm in the entire polymerization.

Abstract: Novel glycopeptide antibiotic derivatives. These derivatives are represented by the formula (aglycon part of glycopeptide antibiotic derivative)-(Sac-NH)—RA [wherein (aglycon part of glycopeptide antibiotic derivative) is the part formed by removing the sugar part from a known glycopeptide antibiotic derivative; (Sac-NH) part is an amino sugar part or a sugar chain part containing an amino sugar; and RA represents, e.g., the formula —X1—Ar1—X2—Y—X3—Ar2 (wherein X1, X2, and X3 each represents 1) a single bond or 2) a heteroatom or heteroatom-containing group selected from the group consisting of —N?, ?N—, —NR1—, —O—, etc.; Y represents —NR2CO— or —CONR2— (wherein R2 represents hydrogen or lower alkyl), etc.)]. These derivatives have antibacterial activity against vancomycin-resistant bacteria.

Abstract: An improved method for cyclization of peptide (H)-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp(NH2) by cystine formation is devised.

Abstract: Protein structures 1 repeating regularly in one, two or three dimensions comprise protein protomers 2 which each comprise at least two monomers 5, 6 genetically fused together. The monomers 5, 6 are monomers of respective oligomer assemblies 3, 4 into which the monomers are assembled to assembly of the protein structure. The first oligomer assembly 3 has rotational symmetry axes including a set of rotational symmetry axes of order N, where N equals 2, 3, 4 or 6. The second oligomer assembly 4 has a rotational symmetry axis of the same order N as said set of rotational symmetry axes of said first oligomer assembly 3. Due to the symmetry of the oligomer assemblies 3, 4, the rotational symmetry axis axes of each second oligomer assembly 4 is aligned with one of said set of rotational symmetry axes of a first oligomer assembly 3 with N protomers being arranged symmetrically therearound.

Abstract: Disclosed herein are novel polypeptides and the nucleic acid sequences that encode them. Also disclosed are antibodies that immunospecifically bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the novel polypeptide, polynucleotide, or antibody specific to the polypeptide. Vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using same are also included. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders involving these novel human nucleic acids and proteins.

Abstract: The present invention relates to a novel human protein called phosphatonin, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.

Abstract: Modified human four helical bundle (4HB) polypeptides and uses thereof are provided.

Abstract: A process for the expression and purification of membrane associated proteins is provided. A process for the expression and purification of membrane proteins such as G-protein coupled receptors is provided. A hybrid polypeptide is constructed from a protein of interest and a peptide tag from the amino-terminus extracellular domain of rhodopsin. A method for purifying the hybrid protein using the rhodopsin tag is provided. Methods of detecting the expressed hybrid are also provided.

Abstract: [Object] It is intended to provide a crystalline maltitol powder less prone to consolidation, which is free from the formation of a lump during delivery or storage thereof, does not require pulverization or re-classification in use, is easy to handle in transfer, package opening, addition or mixing to another food material, and so on, and allows for automated transportation and so on. [Means for Solving the Object] The crystalline maltitol powder less prone to consolidation is obtained by charging crystalline or powdery maltitol into a shelf type dryer, a tunnel-type dryer, a cylindrical container, or the like and subjecting the equipment or container to a treatment wherein an air having a temperature of 30 to 33° C. and a relative humidity of 5% is allowed to flow into the equipment or container from one side thereof and withdrawn out of the other side thereof at a space velocity of 11 to 12 for consecutive 24 hours.

Abstract: The present invention relates to a process for preparing chito-oligosaccharide material by the enzymatic hydrolysis of chitinous materials, such as chitin, chitosan, and squid pen. The results of cell experiment showed that the oligosaccharide material of the invention causes a decrease in survival rate of U937 cell (a human leukemia cell line) to 69-57%; and of CT26 (a mouse rectal carcinoma cell line) to 69-57%. The product of the invention is preferably in form of tablet, capsule, powder, and granules. It may be added to any kind of foods as a nutriment, which is administered orally as an anti-tumor auxiliary.

Abstract: The invention provides a conjugate of functional oligonucleotide with poly(ethylene oxide), polyion complex of the conjugate with cationic polymer, and micelle thereof. The micelle improves stability of the oligonucleotide in animal cells and its specific bindability to target gene.

Abstract: The invention relates to genetic elements capable of improving the levels of expression of operably-linked transcription units. In particular, said genetic elements are derived from the 5? untranslated regions of ribosomal protein genes and may comprise a CpG island. Also provided are vectors and host cells comprising said genetic elements and methods of use to obtain high levels of recombinant gene expression.

Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for deubiquitination enzymes.

Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing Bcl-2.

Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TNF?.

Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for kinases.

Abstract: Processes for preparing individual diastereomers of mono-pegylated rapamycin 42 ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) are provided.

Abstract: Compounds of formula I pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.

Abstract: The present invention relates to an improved process for the preparation of Levofloxacin hemihydrate by adjusting the moisture content of the solvent to about 12% to about 20% during crystallization.

Abstract: Provided are crystalline mycophenolate sodium forms and processes for their preparation.

Abstract: A process for preparing compounds of Formula (I) are described herein as well as key intermediates 1.

Abstract: Methods of preparing 5-alkyl-7H-pyrrolo[2,3-d]pyrimidin-4-ols are described, as are novel compounds useful in their preparation.

Abstract: Heterocyclic amide and imine derivatives, processes for their preparation, compositions comprising them and their use as pesticides What is described are compounds of the formulae (I) and (II) where the symbols and indices have the meanings given in the description. These compounds are suitable for controlling animal pests.

Abstract: Novel opiate intermediate compositions and methods of synthesis that include changing the substitution pattern on the aromatic ring of the pre-Grewe intermediate are provided. The intermediates are morphinane derivatives of formula (10) wherein X is a F or Cl and R is selected from the group consisting of an H, alkyl, aryl, acyl, formyl, COR?, CONHR?, COOR, Bn(benzyl), alkyl(methyl), and sulfonamide SO2CH2COPh.

Abstract: An improved process for the manufacture of Clopidogrel starting from 2-(2-thienyl) ethylamine, which eliminates the isolation of an unstable intermediate like 2-(2-thienyl) ethyl formimine by subjecting it to a one pot cyclization to get 4, 5, 6, 7-tetrahydrothieno (3,2-c) pyridine of Formula II and further reacting with halo-compound of Formula III (where X is Cl or Br) at 20 to 90° C. temperature characterized in a solvent like water and/or dichloroethane in presence of organic or inorganic bases is disclosed herein. This invention further discloses a process for resolution of racemic Clopidogrel into its optical antipodes and converting the dextroclopidogrel base into its known polymorphs namely ‘Form I’ or ‘Form II’ in solvents selected from methyl propyl ketone, methyl isopropyl ketone, diethyl ketone or their mixture thereof, mixture of ethyl acetate and methyl propyl ketone, mixture of ethyl acetate and methyl isopropyl ketone, or mixture of ethyl acetate and diethyl ketone or ethyl acetate.

Abstract: This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to ?-aminotetralin-derived ureas that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.

Abstract: Compounds of Formula 1 where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardiovascular and/or sedatory activity. These compounds of Formula 1 are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors. Compounds of Formula 1 where X is O also have the advantageous property that they have no or only minimal cardiovascular and/or sedatory activity and are useful for treating pain and other conditions with no or only minimal cardiovascular and/or sedatory activity.

Abstract: This invention relates to novel compounds and a process for preparation of montelukast sodium.

Abstract: The invention is directed to compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7a, R7b, W, G1, G2, a, b, c, d and m are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

Abstract: A halogenated benzamide derivative characterized by greater specificity for viral pathogens and less disruptive to beneficial gut microflora, according to formula (III): in which R1 is a halogen atom, and R2-R6 are independently hydrogen, hydroxyl, C1-C4 alkyl, —C1-C4 alkoxy, acyloxy, nitro, halogen, —C(O)R7 where R7 is —C1-C4 alkyl, or, aromatic including salts and hydrates of these compounds and where at least two of R2-R6 are not hydrogen and where at least one of R2-R6 are hydroxy or acyloxy.

Abstract: The present invention relates to a 1-substituted-4-nitroimidazole compound represented by the general formula (1) or a salt thereof, (wherein R is a hydrogen atom, a lower alkoxy group-substituted lower alkyl group, a phenyl-lower alkoxy group-substituted lower alkyl group, a cyano-substituted lower alkyl group, a phenyl-lower alkyl group which may have lower alkoxy groups as the substituents in the phenyl ring or a group of the formula —CH2RA; X is a halogen atom or a group of the formula —S(O)n-R1) and method for preparing the same. The compound of the formula (1) is a useful compound as an intermediate for synthesis of various pharmaceutical and agricultural chemicals, particularly, as intermediates for antitubercular agents.

Abstract: This invention relates to potent potassium channel blocker compounds of Formula (I) or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

Abstract: The invention concerns 2-oxo-1-pyrrolidine derivatives of formula I, wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals. The compounds of the invention are particularly suited for treating neurological disorders such as epilepsy.

Abstract: The present invention relates to novel salt forms of a compound of Formula (I): and processes for their preparation.

Abstract: The present invention relates to a first compound having the formula wherein R is halogen, R1S(O)n or (R1)2NC(X)O; R1 is C1-C8alkyl, C1-C8haloalkyl, aryl-C1-C8-alkyl or aryl; n is 0, 1, 2 or 3; X is O or S; and R3 is C2-C5alkyl or C1-C5haloalkyl, or a salt thereof. The present invention is also directed to a second compound having the formula wherein R is fluorine, bromine, iodine, R1S(O)n or (R1)2NC(X)O; R1 is C1-C8alkyl, C1-C8haloalkyl, aryl-C1-C8alkyl or aryl; n is 0, 1, 2 or 3; X is O or S; and R2 is hydrogen, C1-C4alkyl or C1-C4haloalkyl, with the proviso that R1 is different from C1-C8 alkyl or aryl if X is S, R is different from iodine if R2 is methyl, and R is different from fluorine, bromine or iodine if R2 is hydrogen.